Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures
نویسندگان
چکیده
INTRODUCTION Dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine (eg, clopidogrel) prevents stent related thromboembolic events in cardiac patients and is frequently utilized during neurointerventional surgery. However, recent data suggest that many patients exhibit clopidogrel resistance. Prasugrel-a newer thienopyridine-lowers the rate of cardiac stent thromboses in clopidogrel non-responders but a paucity of data exist regarding its safety and efficacy in neurointerventional surgery. METHODS All patients undergoing neurointerventional surgery by a single interventionalist (CJM) over a 20 month period were retrospectively identified. Charts were reviewed for pre- and post-procedural DAPT regimens, pre-procedural coagulation parameters and procedural complications. RESULTS 76 patients received pre- and post-procedural DAPT for endovascular treatment of an intracerebral aneurysm, dural arteriovenous fistula or intra/extracranial arterial stenosis. 51 patients underwent 55 total procedures and were treated with aspirin/clopidogrel; 25 patients underwent 31 total procedures and were treated with aspirin/prasugrel. Those patients who received aspirin/prasugrel DAPT were identified pre-procedurally to be clopidogrel non-responders. Both treatment groups had a similar percentage of patients undergoing aneurysm coiling, stent assisted aneurysm coiling, aneurysm Onyx embolization, aneurysm pipeline embolization device treatment, extra/intracranial carotid artery angioplasty and stenting, and dural arteriovenous fistula coil embolization. A total of eight (9.3%) hemorrhagic complications were observed, two (3.6%) in the aspirin/clopidogrel group and six (19.4%) in the aspirin/prasugrel group (p=0.02). No differences were noted in hemorrhage rates for each procedure between treatment groups, nor were there any differences in thrombotic complications between groups. CONCLUSION Our results suggest that DAPT with aspirin/prasugrel may predispose to a higher risk of hemorrhage during neurointerventional surgery compared with DAPT with aspirin/clopidogrel.
منابع مشابه
Clopidogrel hyper-response and bleeding risk in neurointerventional procedures.
BACKGROUND AND PURPOSE Antiplatelet therapy is associated with decreased ischemic events after neurointerventional procedures. Antiplatelet resistance negates the protective effects of antiplatelet medication, leading to a higher incidence of ischemic events. A possible link between antiplatelet hyper-response and increased hemorrhagic complications has been inadequately investigated. We aimed ...
متن کاملLast-Recorded P2Y12 Reaction Units Value Is Strongly Associated with Thromboembolic and Hemorrhagic Complications Occurring Up to 6Months after Treatment in Patients with Cerebral Aneurysms Treated with the Pipeline Embolization Device
BACKGROUND AND PURPOSE: A recent study identified a preprocedural P2Y12 reaction units value of 60 or 240 as a strong independent predictor of perioperative thromboembolic and hemorrhagic complications after treatment of cerebral aneurysms with the Pipeline Embolization Device. This study aimed to determine whether a last-recorded P2Y12 reaction units value of 60 or 240 predicts thromboembolic ...
متن کاملPlavix and lumbar puncture
Feb 3, 2016. Quincke performed the first lumbar puncture (LP) in 1891 to relieve of bleeding with thienopyridine derivatives (clopidogrel, ticlopidine) it may . Lumbar puncture (LP) is the most used technique for obtaining cerebrospinal. . clopidogrel associated bleeding risk in patients submitted to spinal anesthesia . Aug 30, 2017. Plavix (Clopidogrel), Prasugrel. (Effient), Ticagrelor (Brili...
متن کاملStarClose vascular closure device: safety and efficacy of deployment and reaccess in a neurointerventional radiology service.
BACKGROUND AND PURPOSE Obtaining safe and effective closure of the femoral access site following neurointerventional procedures can sometimes be challenging, especially in patients on anti-coagulation or anti-platelet therapy. The purpose of this study was to evaluate the safety and efficacy of a novel percutaneous closure device that employs a nitinol clip-mediated extravascular closure strate...
متن کاملTicagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.
Volume 88, Number 12 www.aafp.org/afp American Family Physician 821 Ticagrelor (Brilinta) is a newer, reversible P2Y12 platelet inhibitor. Older, irreversible P2Y12 receptor inhibitors include prasugrel (Effient), clopidogrel (Plavix), and ticlopidine. Ticagrelor is labeled for the prevention of vascular events and death in patients with acute coronary syndrome.1 STEPS new drug reviews cover Sa...
متن کامل